1. Home
  2. NAK vs ABCL Comparison

NAK vs ABCL Comparison

Compare NAK & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Northern Dynasty Minerals Ltd.

NAK

Northern Dynasty Minerals Ltd.

HOLD

Current Price

$2.07

Market Cap

1.1B

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$4.14

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NAK
ABCL
Founded
1983
2012
Country
Canada
Canada
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
2002
2020

Fundamental Metrics

Financial Performance
Metric
NAK
ABCL
Price
$2.07
$4.14
Analyst Decision
Strong Buy
Buy
Analyst Count
2
5
Target Price
$2.50
$7.75
AVG Volume (30 Days)
7.4M
4.5M
Earning Date
11-13-2025
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$35,325,000.00
Revenue This Year
N/A
$25.45
Revenue Next Year
N/A
$10.07
P/E Ratio
N/A
N/A
Revenue Growth
N/A
7.17
52 Week Low
$0.55
$1.89
52 Week High
$2.98
$6.52

Technical Indicators

Market Signals
Indicator
NAK
ABCL
Relative Strength Index (RSI) 50.30 56.45
Support Level $2.00 $4.08
Resistance Level $2.25 $4.38
Average True Range (ATR) 0.15 0.28
MACD -0.02 0.05
Stochastic Oscillator 43.02 60.23

Price Performance

Historical Comparison
NAK
ABCL

About NAK Northern Dynasty Minerals Ltd.

Northern Dynasty Minerals Ltd is a mineral exploration company. It has a single operating segment of acquisition, exploration, and development of mineral properties. Its core asset is the Pebble Project located in Alaska, USA. The Pebble project is seeking to develop a deposit of copper, gold, molybdenum, and silver into a modern mining operation.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

Share on Social Networks: